These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37209613)

  • 1. Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.
    Liang Q; Wang B; Zou F; Guo G; Wang W; Wang W; Liu Q; Shen L; Hu C; Wang W; Wang A; Huang T; He Y; Xia R; Ge J; Liu J; Liu Q
    Eur J Med Chem; 2023 Aug; 256():115411. PubMed ID: 37209613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
    Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
    J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening.
    Duan Z; Liu J; Niu L; Wang J; Feng M; Chen H; Luo C
    Bioorg Med Chem; 2019 Aug; 27(15):3229-3236. PubMed ID: 31208797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and structure-activity-relationship study of novel conformationally restricted indane analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
    Zheng Q; Tang S; Fu X; Chen Z; Ye Y; Lan X; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5262-5266. PubMed ID: 29079473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
    Xie X; Baird D; Bowen K; Capka V; Chen J; Chenail G; Cho Y; Dooley J; Farsidjani A; Fortin P; Kohls D; Kulathila R; Lin F; McKay D; Rodrigues L; Sage D; Touré BB; van der Plas S; Wright K; Xu M; Yin H; Levell J; Pagliarini RA
    Structure; 2017 Mar; 25(3):506-513. PubMed ID: 28132785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
    Deng G; Shen J; Yin M; McManus J; Mathieu M; Gee P; He T; Shi C; Bedel O; McLean LR; Le-Strat F; Zhang Y; Marquette JP; Gao Q; Zhang B; Rak A; Hoffmann D; Rooney E; Vassort A; Englaro W; Li Y; Patel V; Adrian F; Gross S; Wiederschain D; Cheng H; Licht S
    J Biol Chem; 2015 Jan; 290(2):762-74. PubMed ID: 25391653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity-relationship study of novel imidazole cyclopropyl amine analogues for mutant isocitric dehydrogenase 1 (IDH1) inhibitors.
    Zheng Q; Chen Z; Wan H; Tang S; Ye Y; Xu Y; Jiang L; Ding J; Geng M; Huang M; Huang Y
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3808-3812. PubMed ID: 30413349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
    Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
    Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
    Wen H; Cho HR; Yun T; Kim H; Park CK; Lee SH; Choi SH; Park S
    J Neurochem; 2015 Jan; 132(2):183-93. PubMed ID: 25251602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
    Lin J; Lu W; Caravella JA; Campbell AM; Diebold RB; Ericsson A; Fritzen E; Gustafson GR; Lancia DR; Shelekhin T; Wang Z; Castro J; Clarke A; Gotur D; Josephine HR; Katz M; Diep H; Kershaw M; Yao L; Kauffman G; Hubbs SE; Luke GP; Toms AV; Wang L; Bair KW; Barr KJ; Dinsmore C; Walker D; Ashwell S
    J Med Chem; 2019 Jul; 62(14):6575-6596. PubMed ID: 31199148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
    Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
    Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
    Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
    Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
    Jones S; Ahmet J; Ayton K; Ball M; Cockerill M; Fairweather E; Hamilton N; Harper P; Hitchin J; Jordan A; Levy C; Lopez R; McKenzie E; Packer M; Plant D; Simpson I; Simpson P; Sinclair I; Somervaille TC; Small H; Spencer GJ; Thomson G; Tonge M; Waddell I; Walsh J; Waszkowycz B; Wigglesworth M; Wiseman DH; Ogilvie D
    J Med Chem; 2016 Dec; 59(24):11120-11137. PubMed ID: 28002956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
    Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
    J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
    Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
    Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.
    Zhou X; Zheng M; Zhao N; Hu Y; Yang K; Huo J; Liu G; Huang J; Chen L; Zhou Y; Li H
    Bioorg Chem; 2022 Feb; 119():105569. PubMed ID: 34954572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
    Liu X; Hu Y; Gao A; Xu M; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
    Bioorg Med Chem; 2019 Feb; 27(4):589-603. PubMed ID: 30600148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation.
    Wen F; Gui G; Wang X; Qin A; Ma T; Chen H; Li C; Zha X
    J Med Chem; 2024 Jun; 67(11):8667-8692. PubMed ID: 38651495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.